menu

Pediatric Neuroblastoma Treatment Market

Schedule Call

Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy), Risk Group (Low-Risk, Intermediate-Risk), End User (Hospitals, Cancer Specialty Centers) – Global Outlook & Forecast 2024-2032

GR - 710158 Category: Therapeutics

Number of pages: 120  |  Report Format: PDF  |  Published date: January 28, 2022

Historical Years – 2022  |  Base Year – 2023  |  Forecasted Years – 2024 to 2032


Pediatric Neuroblastoma Treatment Market Scope

Report Attribute

Details

Market Size Value in 2023

US$ 2.4 billion

Revenue Forecast in 2032

US$ 5.2 billion

CAGR

8.9%

Base Year for Estimation

2023

Forecast Period

2024 to 2032

Historical Year

2022

Segments Covered

Treatment Type, Risk Group, End User, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global pediatric neuroblastoma treatment market was valued at US$ 2.4 billion in 2023 and is expected to register a revenue CAGR of 8.9% to reach US$ 5.2 billion by 2032.

Introduction
The "Global Pediatric Neuroblastoma Treatment Market Report 2022-2032" offers an extensive analysis of the global Pediatric Neuroblastoma Treatment market, providing valuable insights into the latest trends, market drivers, challenges, and future outlook. This report is essential for stakeholders seeking to understand the evolving landscape and capitalize on emerging opportunities in the Pediatric Neuroblastoma sector.

Geographical Scope and Study Timeline

  • Regions Covered: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
  • Study Period: 2022-2032
  • Market Segmentation: By Treatment Type, Risk Group, End User and Region

Pediatric Neuroblastoma Treatment Market Overview
This section provides a detailed overview of Pediatric Neuroblastoma, including the current state of research, technological advancements, and key developments. The report covers disease mechanisms, patient demographics, and current treatment protocols, setting the stage for a deeper understanding of the market.

Epidemiology and Patient Demographics
Explore the epidemiological trends of Pediatric Neuroblastoma across key regions, with a focus on prevalence, incidence, and patient population dynamics. This section provides a foundation for understanding the potential market size and growth opportunities.

Treatment Landscape and Pipeline Review
The report includes a comprehensive review of the treatment landscape, covering both established therapies and those in the pipeline. Each therapy is evaluated based on its clinical efficacy, safety profile, and market potential, offering insights into the future of Pediatric Neuroblastoma treatment.

Market Dynamics and Trends

  • Key Market Drivers: Analysis of the factors driving market growth, including innovation in treatment modalities, rising disease awareness, and favorable regulatory environments.
  • Market Challenges: Discussion of barriers to market growth, such as high development costs, regulatory hurdles, and competition from alternative therapies.
  • Emerging Trends: Identification of emerging trends, including the adoption of personalized medicine, advancements in biotechnology, and shifts in healthcare policy.

Market Forecast and Opportunity Analysis

  • Market Projections: Detailed market projections for the Pediatric Neuroblastoma Treatment market from 2022 to 2032, segmented by region, treatment type, risk group, and end user.
  • Opportunity Analysis: Identification of key opportunities for market entry, expansion, and innovation, with a focus on unmet needs and market gaps.

Key Opinion Leader (KOL) Insights: Primary research insights from KOLs and Subject Matter Experts (SMEs) in the Pediatric Neuroblastoma domain, offering perspectives on treatment patterns, emerging trends, and market opportunities.

Strategic Insights and Recommendations
The report concludes with actionable insights and recommendations for stakeholders looking to navigate the Pediatric Neuroblastoma Treatment market successfully. Strategies for market entry, product development, and competitive positioning are discussed, helping clients to achieve long-term success.

Competitive Landscape
This section profiles the leading companies in the Pediatric Neuroblastoma Treatment market, highlighting their product portfolios, R&D activities, and strategic initiatives. The report also provides an analysis of market share by key players, offering a clear picture of the competitive environment. The prominent players operating in the global pediatric neuroblastoma treatment market are:

  • Bayer AG
  • Pfizer Inc
  • Apeiron Biologics AG
  • Baxter 
  • United Therapeutics Corporation
  • Y-mAbs Therapeutics, Inc
  • Cellectar Biosciences, Inc
  • Clarity Pharmaceuticals
  • Provectus Biopharmaceuticals, Inc
  • Scorpion Therapeutics

Frequently Asked Questions About This Report

Pediatric neuroblastoma is a type of cancer that develops in immature nerve cells called neuroblasts. It is the most common solid tumor found in infants and young children, typically occurring in children under the age of five.

Collaboration and partnerships play a significant role in advancing pediatric neuroblastoma treatment. Key market players collaborate with academic institutions, research organizations, and other industry partners to leverage their expertise, access patient populations, and jointly conduct clinical trials.

The prominent players operating in the global pediatric neuroblastoma treatment Bayer AG, Pfizer Inc, Apeiron Biologics AG, Baxter, and United Therapeutics Corporation.

The global pediatric neuroblastoma treatment market growth is estimated to grow at a revenue CAGR of 8.9% during the forecast period from 2024 to 2032.

The estimated size of the global pediatric neuroblastoma treatment market in 2032 is US$ 5.2 billion.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2022
      2. Base Year – 2023
      3. Forecast Years – 2024 to 2032
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2023) 
    3. Regulatory Landscape 
    4. Reimbursement Scenario 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Chemotherapy
    2. Immunotherapy
    3. Targeted Therapy
    4. Others 
  6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY RISK GROUP
    1. Low-Risk
    2. Intermediate-Risk
    3. High-Risk
  7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY END USER
    1. Hospitals
    2. Cancer Specialty Center
    3. Others 
  8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Pediatric Neuroblastoma Treatment Market
      1. North America Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. North America Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. North America Pediatric Neuroblastoma Treatment Market, by End User
      4. North America Pediatric Neuroblastoma Treatment Market, by Country
        1. U.S.
          1. U.S. Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. U.S. Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. U.S. Pediatric Neuroblastoma Treatment Market, by End User
        2. Canada
          1. Canada Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Canada Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Canada Pediatric Neuroblastoma Treatment Market, by End User
    2. Europe Pediatric Neuroblastoma Treatment Market
      1. Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Europe Pediatric Neuroblastoma Treatment Market, by Risk Group 
      3. Europe Pediatric Neuroblastoma Treatment Market, by End User
      4. Europe Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. Germany
          1. Germany Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Germany Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Germany Pediatric Neuroblastoma Treatment Market, by End User 
        2. U.K.
          1. U.K. Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. U.K. Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. U.K. Pediatric Neuroblastoma Treatment Market, by End User 
        3. France
          1. France Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. France Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. France Pediatric Neuroblastoma Treatment Market, by End User
        4. Spain
          1. Spain Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Spain Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Spain Pediatric Neuroblastoma Treatment Market, by End User 
        5. Italy
          1. Italy Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Italy Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Italy Pediatric Neuroblastoma Treatment Market, by End User 
        6. Rest of Europe 
          1. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Europe Pediatric Neuroblastoma Treatment Market, by End User 
    3. Asia Pacific Pediatric Neuroblastoma Treatment Market
      1. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User
      4. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. China
          1. China Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. China Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. China Pediatric Neuroblastoma Treatment Market, by End User 
        2. Japan
          1. Japan Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Japan Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Japan Pediatric Neuroblastoma Treatment Market, by End User
        3. India
          1. India Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. India Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. India Pediatric Neuroblastoma Treatment Market, by End User 
        4. South Korea
          1. South Korea Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. South Korea Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. South Korea Pediatric Neuroblastoma Treatment Market, by End User
        5. Australia
          1. Australia Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Australia Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Australia Pediatric Neuroblastoma Treatment Market, by End User 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User 
    4. Latin America Pediatric Neuroblastoma Treatment Market
      1. Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Latin America Pediatric Neuroblastoma Treatment Market, by End User 
      4. Latin America Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. Brazil
          1. Brazil Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Brazil Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Brazil Pediatric Neuroblastoma Treatment Market, by End User 
        2. Mexico
          1. Mexico Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Mexico Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Mexico Pediatric Neuroblastoma Treatment Market, by End User
        3. Argentina
          1. Argentina Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Argentina Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Argentina Pediatric Neuroblastoma Treatment Market, by End User 
        4. Rest of Latin America
          1. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by End User
    5. Middle East & Africa Pediatric Neuroblastoma Treatment Market
      1. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User 
      4. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. GCC Countries
          1. GCC Countries Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. GCC Countries Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. GCC Countries Pediatric Neuroblastoma Treatment Market, by End User 
        2. South Africa
          1. South Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. South Africa Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. South Africa Pediatric Neuroblastoma Treatment Market, by End User
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User 
  9. COMPANY PROFILES        
    1. Bayer AG
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Pfizer Inc
    3. Apeiron Biologics AG
    4. Baxter 
    5. United Therapeutics Corporation
    6. Y-mAbs Therapeutics, Inc
    7. Cellectar Biosciences, Inc
    8. Clarity Pharmaceuticals
    9. Provectus Biopharmaceuticals, Inc
    10. Scorpion Therapeutics

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

  1. Global Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million)
  2. Global Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  3. Global Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  4. Global Pediatric Neuroblastoma Treatment Market, by Region, 2022-2032 (US$ Million) 
  5. North America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  6. North America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  7. North America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  8. North America Pediatric Neuroblastoma Treatment Market, by Country, 2022-2032 (US$ Million) 
  9. U.S. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  10. U.S. Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  11. U.S. Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  12. Canada Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  13. Canada Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  14. Canada Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  15. Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  16. Europe Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  17. Europe Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  18. Europe Pediatric Neuroblastoma Treatment Market, by Country/Region, 2022-2032 (US$ Million) 
  19. Germany Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  20. Germany Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  21. Germany Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  22. U.K. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  23. U.K. Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  24. U.K. Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  25. France Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  26. France Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  27. France Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  28. Italy Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  29. Italy Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  30. Italy Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  31. Spain Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  32. Spain Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  33. Spain Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  34. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  35. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  36. Rest of Europe Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  37. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  38. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  39. Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  40. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Country/Region, 2022-2032 (US$ Million) 
  41. China Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  42. China Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  43. China Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  44. Japan Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  45. Japan Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  46. Japan Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  47. India Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  48. India Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  49. India Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  50. South Korea Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  51. South Korea Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  52. South Korea Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  53. Australia Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  54. Australia Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  55. Australia Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  56. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  57. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  58. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  59. Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  60. Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  61. Latin America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  62. Latin America Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021–2031 (US$ Million)
  63. Brazil Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  64. Brazil Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  65. Brazil Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  66. Mexico Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  67. Mexico Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  68. Mexico Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  69. Argentina Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  70. Argentina Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  71. Argentina Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  72. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  73. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  74. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  75. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  76. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  77. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by End User 2021–2031 (US$ Million)
  78. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021–2031 (US$ Million)
  79. GCC Countries Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  80. GCC Countries Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  81. GCC Countries Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  82. South Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  83. South Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  84. South Africa Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  85. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2022-2032 (US$ Million) 
  86. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  87. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)

List of Figures

  1. Pediatric Neuroblastoma Treatment Market Ecosystem  
  2. Snapshot of Global Pediatric Neuroblastoma Treatment Market, 2022-2032 
  3. Snapshot of Global Pediatric Neuroblastoma Treatment Market, by Region, 2022-2032 
  4. Global Pediatric Neuroblastoma Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Pediatric Neuroblastoma Treatment Market: Key Players & Competitive Positioning (2023) 
  6. Pediatric Neuroblastoma Treatment: Market Dynamics 
  7. Global Chemotherapy for Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  8. Global Immunotherapy for Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  9. Global Targeted Therapy for Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  10. Global Others for Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  11. Global Low-Risk Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  12. Global Intermediate-Risk Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  13. Global High-Risk Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  14. Global Pediatric Neuroblastoma Treatment Market for Hospitals, 2022-2032 (US$ Million) 
  15. Global Pediatric Neuroblastoma Treatment Market for Cancer Specialty Centers, 2022-2032 (US$ Million) 
  16. Global Pediatric Neuroblastoma Treatment Market for Others, 2022-2032 (US$ Million) 
  17. North America Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  18. U.S. Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  19. Canada Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  20. Europe Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  21. Germany Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  22. U.K. Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  23. France Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  24. Italy Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  25. Spain Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  26. Rest of Europe Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  27. Asia Pacific Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  28. China Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  29. Japan Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  30. India Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  31. South Korea Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  32. Australia Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  33. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  34. Latin America Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  35. Brazil Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  36. Mexico Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  37. Argentina Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million)
  38. Rest of Latin America Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million)
  39. Middle East & Africa Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million)
  40. GCC Countries Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  41. South Africa Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million) 
  42. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, 2022-2032 (US$ Million)
  43. Bayer AG Revenue from 2021 Onwards (US$ Million)
  44. Pfizer Inc Revenue from 2021 Onwards (US$ Million)
  45. Apeiron Biologics AG Revenue from 2021 Onwards (US$ Million)
  46. Baxter Revenue from 2021 Onwards (US$ Million)
  47. United Therapeutics Corporation Revenue from 2021 Onwards (US$ Million)
  48. Y-mAbs Therapeutics, Inc Revenue from 2021 Onwards (US$ Million)
  49. Cellectar Biosciences, Inc Revenue from 2021 Onwards (US$ Million)
  50. Clarity Pharmaceuticals Revenue from 2021 Onwards (US$ Million)
  51. Provectus Biopharmaceuticals, Inc Revenue from 2021 Onwards (US$ Million)
  52. Scorpion Therapeutics Revenue from 2021 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Pediatric Neuroblastoma Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Pediatric Neuroblastoma Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports